Auteurs
Analysis
UK
Racine
Analysis
UK
Exploration
Accueil
Racine
Racine

Serveur d'exploration sur les relations entre la France et l'Australie - Analysis (UK)

Index « Auteurs » - entrée « Michael Larsen »
Attention, ce site est en cours de développement !
Attention, site généré par des moyens informatiques à partir de corpus bruts.
Les informations ne sont donc pas validées.
Michael Lappin < Michael Larsen < Michael Lassmann  Facettes :

List of bibliographic references

Number of relevant bibliographic references: 2.
Ident.Authors (with country if any)Title
000779 (2016) Sobha Sivaprasad [Royaume-Uni] ; Stephane A. Regnier [Suisse] ; Franck Fajnkuchen [France] ; Jonathan Wright [Royaume-Uni] ; Alan R. Berger [Canada] ; Paul Mitchell [Australie] ; Michael Larsen [Danemark]Using Patient-Level Data to Develop Meaningful Cross-Trial Comparisons of Visual Impairment in Individuals with Diabetic Macular Edema
002751 (2010) Pascale Massin [France] ; Francesco Bandello [Italie] ; Justus G. Garweg [Suisse] ; Lutzl. Hansen [Allemagne] ; Simon P. Harding [Royaume-Uni] ; Michael Larsen [Danemark] ; Paul Mitchell [Australie] ; Dianne Sharp [Nouvelle-Zélande] ; U. E. K. Wolf-Schnurrbusch [Suisse] ; Margarita Gekkieva [Suisse] ; Andreas Weichselberger [Suisse] ; Sebastian Wolf [Suisse]Safety and Efficacy of Ranibizumab in Diabetic Macular Edema (RESOLVE Study*): A 12-month, randomized, controlled, double-masked, multicenter phase II study

List of associated KwdEn.i

Nombre de
documents		Descripteur
1Aged
1Angiogenesis Inhibitors (therapeutic use)
1Antiangiogenic agent
1Diabetes mellitus
1Diabetic Retinopathy (complications)
1Diabetic Retinopathy (pathology)
1Double blind study
1Endocrinology
1Female
1Human
1Humans
1Immunomodulator
1Intravitreal Injections
1Laser Therapy (methods)
1Macular Edema (diagnosis)
1Macular Edema (drug therapy)
1Macular Edema (etiology)
1Male
1Metabolic diseases
1Middle Aged
1Models, Statistical
1Multicenter study
1Nutrition
1Patient Outcome Assessment
1Patient Selection
1Phase II trial
1Randomization
1Ranibizumab
1Ranibizumab (therapeutic use)
1Receptors, Vascular Endothelial Growth Factor (therapeutic use)
1Recombinant Fusion Proteins (therapeutic use)
1Retinal edema
1Safety
1Toxicity
1Treatment
1Treatment efficiency
1Vascular Endothelial Growth Factor A (antagonists & inhibitors)
1Vascular endothelium growth factor
1Vision Disorders (diagnosis)
1Vision Disorders (etiology)
1Visual Acuity

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/UK/Analysis

HfdIndexSelect -h $EXPLOR_AREA/Data/UK/Analysis/Author.i -k "Michael Larsen" 

HfdIndexSelect -h $EXPLOR_AREA/Data/UK/Analysis/Author.i  \
                -Sk "Michael Larsen" \
         | HfdSelect -Kh $EXPLOR_AREA/Data/UK/Analysis/biblio.hfd

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Asie
   |area=    AustralieFrV1
   |flux=    UK
   |étape=   Analysis
   |type=    indexItem
   |index=    Author.i
   |clé=    Michael Larsen
}}
Wicri

This area was generated with Dilib version V0.6.33.
Data generation: Tue Dec 5 10:43:12 2017. Site generation: Tue Mar 5 14:07:20 2024